A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80
a study on Parkinson's Disease
Parkinson Disease, Early-stage Parkinson Disease, BIIB122, BIIB122 225 mg
Lead Scientist at UCSF
- Marta San Luciano Palenzuela
Dr. Marta San Luciano specializes in diagnosing and managing movement disorders, including Parkinson's disease, dystonia, tremor and myoclonus, in both children and adults.
- accepting new patients
- Start Date
- Completion Date
- Click here to learn more about this trial, visit our study website.
- Phase 2 Parkinson's Disease Research Study
- Study Type
- Expecting 640 study participants
- Last Updated